Tristan Manalac is a journalist for BioSpace, focusing on the pharmaceutical and biotech industries. With a keen interest in drug approvals, clinical trial data, and industry developments, Tristan provides insightful coverage of the latest advancements and challenges in the field.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
International
Tristan Manalac's coverage predominantly focuses on the healthcare and pharmaceutical industry, particularly FDA approvals, drug development, and related market movements. His reliance on press releases and data citations suggests a preference for fact-based reporting.
Given his focus on specific companies and regulatory developments in the pharmaceutical industry, Tristan is likely to be responsive to pitches from experts with direct knowledge of relevant drugs, therapies or regulatory processes. Additionally, he may be interested in insights into market trends impacting drug pricing or innovative approaches in drug development.
While geographic focus isn't specified, considering that pharma news often has global implications due to multinational companies involved in research and distribution of drugs worldwide would also be important when reaching out to him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Tristan, Manalac
Pictured: AstraZeneca signage at its office in Sweden/iStock, Wirestock
By: Tristan Manalac
Reeling from “endemic-level demand” for its COVID-19 vaccine, BioNTech on Monday reported a steep decline in revenues and a loss per share that fell short of analysts’ consensus estimates for the first quarter of 2024.
By: Tristan Manalac
The Federal Trade Commission has asked for an additional 30 days for its review of Novo Nordisk’s $16.5 billion acquisition of Catalent, with the companies expecting to complete the merger by the end of 2024.
By: Tristan Manalac
Following an upsized IPO earlier this year, CG Oncology on Friday posted promising Phase III data for cretostimogene, which elicited a 75% complete response rate in high-risk non-muscle invasive bladder cancer patients.
By: Tristan Manalac
In a joint conference event on Monday, cell therapy pioneer Carl June revealed unpublished results showing that in around 1,500 patients treated with CAR-T therapies, no cases of secondary malignancy could be definitively linked to the treatment.
By: Tristan Manalac
ADC Therapeutics is positioning Zynlonta for a label expansion with new Phase II data showing that the treatment can elicit high rates of complete response in patients with relapsed or refractory marginal zone lymphoma.
By: Tristan, Manalac
Pictured: 3D illustration of stem cells used for cell therapy/iStock, Maksim Tkachenko
Pictured: Novo Nordisk's corporate headquarters in Denmark/iStock, Ole Schwander
By: Tristan, Manalac
Pictured: Businessmen shaking hands after closing a deal/iStock, Tippapatt
By: Tristan Manalac
Anticipating approval for its COPD therapy ensifentrine, Verona has entered into a $650 million financing deal with Oaktree Capital Management and OMERS Life Sciences.
(833) 317-6278 